Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD5634 in Healthy Subjects
NCT02679729Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of azd5634 in cystic fibrosis (CF) (8 arms), sponsored by AstraZeneca. Primary endpoint: Safety and Tolerability of AZD5634. Started Feb 2016; status: completed.
02
Drugs
azd5634
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02679729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679729.